Pfizer Inc. is a biopharmaceutical company engaged in the discovery, development, manufacture, marketing, sale and distribution of medicines and vaccines. Its business is organized around a Biopharma segment covering therapeutic areas including oncology, internal medicine, vaccines, and inflammation and immunology, along with a contract development and manufacturing operation and a hospital and biosimilars product line.
| Income statement · $ millions | 2025 | 2024 | 2023 | |
|---|---|---|---|---|
| Total revenues | 62,579 | 63,627 | 59,553 | 4 |
| · Product | 51,663 | 53,816 | 50,914 | |
| · Royalty | 1,650 | 1,423 | 1,058 | |
| · Other (filed total less lines shown) | 9,266 | 8,388 | 7,581 | |
| Cost of revenue | 16,067 | 17,851 | 24,954 | 1 |
| Selling, general and administrative | 13,794 | 14,730 | 14,771 | 1 |
| Depreciation, depletion and amortization | 6,592 | 7,013 | 6,290 | |
| Impairments | 4,940 | 3,295 | 3,024 | |
| Interest expense | 2,671 | 3,091 | 2,209 | |
| Other income (expense), net | (6,724) | (4,388) | (222) | |
| Income before income taxes | 7,520 | 8,023 | 1,058 | |
| Income tax provision | (266) | (28) | (1,115) | |
| — of which current | 1,866 | 2,074 | 2,328 | |
| Net income incl. noncontrolling interests | 7,812 | 8,062 | 2,158 | |
| Less: noncontrolling interests | 41 | 31 | 39 | |
| Net income attributable to common | 7,771 | 8,031 | 2,119 | 1 |
| Diluted earnings per share | $1.36 | $1.41 | $0.37 | 1 |
| Weighted-average diluted shares | 5,713 | 5,700 | 5,709 |
| Cash flow · $ millions | 2025 | 2024 | 2023 | |
|---|---|---|---|---|
| Net income incl. noncontrolling interests | 7,812 | 8,062 | 2,158 | |
| Depreciation, depletion and amortization | 6,592 | 7,013 | 6,290 | |
| Share-based compensation | 799 | 877 | 525 | |
| Deferred income taxes | (2,133) | (2,102) | (3,442) | |
| Change in receivables | 263 | 109 | (347) | |
| Change in inventories | (561) | 854 | 1,169 | |
| Net cash provided by operating activities | 11,704 | 12,744 | 8,700 | 4 |
| Capital expenditure | 2,629 | 2,909 | 3,907 | 1 |
| Acquisitions, net of cash | 6,927 | 0 | 43,430 | |
| Net cash used in investing activities | (1,351) | 2,652 | (32,278) | |
| Repurchases of common stock | — | 0 | 0 | 1 |
| Debt issued | 9,678 | 0 | 30,831 | |
| Debt repaid | 6,757 | 2,250 | 2,569 | |
| Net cash used in financing activities | (10,304) | (17,140) | 26,066 | |
| Cash and equivalents at end of period | 1,197 | 1,107 | 2,917 |
| Balance sheet · $ millions | 2025 | 2024 | |
|---|---|---|---|
| Cash and cash equivalents | 1,142 | 1,043 | |
| Receivables, net | 11,874 | 11,463 | 1 |
| Inventories | 10,654 | 10,851 | 1 |
| Total current assets | 42,898 | 50,358 | |
| Property, plant and equipment, net | 19,317 | 18,393 | |
| Goodwill | 71,264 | 68,527 | 1 |
| Intangible assets, net | 31,510 | 35,848 | |
| Total assets | 208,160 | 213,396 | 1 |
| Accounts payable | 5,240 | 5,633 | |
| Current debt | 3,154 | 6,946 | |
| Total current liabilities | 36,984 | 42,995 | |
| Long-term debt | 61,641 | 57,405 | |
| Total liabilities | 121,385 | 124,899 | |
| Stockholders' equity | 86,476 | 88,203 | |
| Noncontrolling interests | 299 | 294 | |
| Total equity | 86,775 | 88,497 |
| Revenue by segment · as filed · $ millions | FY2025 | Share |
|---|---|---|
| Biopharma | 61,199 | 97.8% |
| Total revenues, as filed | 62,579 | 100.0% |
Single reportable segment: no segment breakdown filed.
| Revenue by product or service · as filed · $ millions | FY2025 | Share |
|---|---|---|
| Product | 51,663 | 82.6% |
| Royalty | 1,650 | 2.6% |
| Other (filed total less lines shown) | 9,266 | 14.8% |
| Total revenues, as filed | 62,579 | 100.0% |
Product lines cover 85% of filed revenue; the rest is not tagged on this axis.
| Revenue by geography · as filed · $ millions | FY2025 | Share |
|---|---|---|
| U.S. | 37,078 | 59.2% |
| Developed Markets | 16,188 | 25.9% |
| Emerging Markets | 9,313 | 14.9% |
| Total revenues, as filed | 62,579 | 100.0% |
Geographic lines sum to the filed total.
Lines render when they sum to the filed total within 0.5 percent. A reconciling line the company filed closes the gap at any size, and the table is split: every line shown is filed, nothing is implied. A computed line, the filed total less the lines shown, closes up to 5 percent of the total; beyond that the table is partial and says so. Members that add to more than the filed total are a conflict and are not shown. The tolerance is 0.5 percent of the filed total or 2 million dollars, whichever is larger; for a filed total under 400 million dollars the floor is the binding one and the table says within tolerance. Every figure is as filed, in millions of dollars; shares are arithmetic on filed lines.
| Largest FY/FY moves · $ millions, ranked by |Δ| | FY2025 | FY2024 | Δ $ | Δ % | Reading |
|---|---|---|---|---|---|
| Total current assets · BS | 42,898 | 50,358 | −7,460 | -14.8% | — |
| Net cash used in financing activities · CF | (10,304) | (17,140) | +6,836 | +39.9% | — |
| Total current liabilities · BS | 36,984 | 42,995 | −6,011 | -14.0% | — |
| Total assets · BS | 208,160 | 213,396 | −5,236 | -2.5% | — |
| Debt repaid · CF | 6,757 | 2,250 | +4,507 | +200.3% | ◐ outsized |
| Intangible assets, net · BS | 31,510 | 35,848 | −4,338 | -12.1% | — |
| Long-term debt · BS | 61,641 | 57,405 | +4,236 | +7.4% | — |
| Net cash used in investing activities · CF | (1,351) | 2,652 | −4,003 | -150.9% | ◐ outsized |
| Current debt · BS | 3,154 | 6,946 | −3,792 | -54.6% | ◐ outsized |
| Total liabilities · BS | 121,385 | 124,899 | −3,514 | -2.8% | — |
| Goodwill · BS | 71,264 | 68,527 | +2,737 | +4.0% | — |
| Other income (expense), net · IS | (6,724) | (4,388) | −2,336 | -53.2% | — |
| · Product · IS | 51,663 | 53,816 | −2,153 | -4.0% | — |
| Cost of revenue · IS | 16,067 | 17,851 | −1,784 | -10.0% | — |
| Business quality — Buffett/Munger screen · deterministic · not part of the filing score | Value | Reading |
|---|---|---|
| Return on equity net income ÷ average of start- and end-of-year equity | 8.9% sector median 13.2% | adequate |
| Share count, year-end (year-end shares − prior year-end) ÷ prior year-end | +0.3% sector median -0.3% | flat |
| Debt to equity (current debt + long-term debt) ÷ year-end equity | 0.75 sector median 0.64 | moderate |
| FCF consistency, 5yr operating cash flow − capital expenditure, per year | positive 5 of 5 | consistent |
| Margin stability pre-tax income ÷ revenue, swing across up to five years | pre-tax margin 12.0% sector median 15.1% | volatile |
| Quarterly · as filed in 10-Q/10-K · $ millions | MAR 25 | JUN 25 | SEP 25 | MAR 26 | JUN 26 |
|---|---|---|---|---|---|
| Total revenues | 13,715 | 14,653 | 16,654 | 14,451 | 15,034 |
| Cost of revenue | 2,845 | 3,778 | 4,172 | 3,548 | 4,092 |
| Selling, general and administrative | 3,031 | 3,415 | 3,186 | 2,961 | 3,411 |
| Depreciation, depletion and amortization | 1,618 | 1,625 | 1,662 | 1,613 | 1,622 |
| Impairments | 224 | 93 | 260 | 0 | 4,325 |
| Interest expense | 654 | 654 | 652 | 668 | 667 |
| Other income (expense), net | (953) | (739) | (517) | (861) | (3,716) |
| Income before income taxes | 2,785 | 3,044 | 3,334 | 3,170 | (653) |
| Income tax provision | (189) | 141 | (216) | 461 | (407) |
| Net income incl. noncontrolling interests | 2,973 | 2,928 | 3,550 | 2,696 | (237) |
| Less: noncontrolling interests | 6 | 18 | 9 | 8 | 10 |
| Net income attributable to common | 2,967 | 2,910 | 3,541 | 2,687 | (248) |
| Diluted earnings per share | $0.52 | $0.51 | $0.62 | $0.47 | $-0.04 |
| Weighted-average diluted shares | 5,710 | 5,706 | 5,714 | 5,731 | 5,699 |
| Net cash provided by operating activities | 2,335 | — | — | 2,615 | — |
| Largest QoQ moves · latest vs prior filed quarter | Prior | Latest | Δ $ | Δ % |
|---|---|---|---|---|
| Income before income taxes | 3,170 | (653) | −3,823 | -120.6% |
| Net income attributable to common | 2,687 | (248) | −2,935 | -109.2% |
| Net income incl. noncontrolling interests | 2,696 | (237) | −2,933 | -108.8% |
| Other income (expense), net | (861) | (3,716) | −2,855 | -331.6% |
| Income tax provision | 461 | (407) | −868 | -188.3% |
| Total revenues | 14,451 | 15,034 | +583 | +4.0% |
| Cost of revenue | 3,548 | 4,092 | +544 | +15.3% |
| Selling, general and administrative | 2,961 | 3,411 | +450 | +15.2% |
| Ownership — insiders & floatForm 4 + 10-K cover · open-market trades only | Value | Reading |
|---|---|---|
| Public float | $138,000M | 10-K cover · as of 2025-06-29 |
| Insider Form 4s, 90d | 17 filings · 3 buys / 1 sells | net buying · +$2,876,849 |
| · Bourla Albert | BUY $1,000,920 | Form 4 filed 2026-08-12 · open market |
| · Blaylock Ronald E | BUY $998,821 | Form 4 filed 2026-08-05 · open market |
| · Buckley Mortimer J | BUY $960,369 | Form 4 filed 2026-08-05 · open market |
| · Damico Jennifer B. | SELL $83,261 | Form 4 filed 2026-08-06 · open market |
| Insider ownership % | — | needs the proxy statement — not read yet, never estimated |
| · The Vanguard Group (1) | 8.97 % | 5%+ holder · DEF 14A filed 2026-03-12 |
| · BlackRock, Inc. (2) | 7.70 % | 5%+ holder · DEF 14A filed 2026-03-12 |
| · State Street Corporation (3) | 5.10 % | 5%+ holder · DEF 14A filed 2026-03-12 |
| Institutional % | 3 holders of 5%+ named | full 13F total pending — never estimated |
Not investment advice. DHI Signal publishes impersonal, rules-based research; no recommendation to buy or sell any security is made or implied. Every statement figure is transcribed from Pfizer's Form 10-K for FY2025 (accession 0000078003-26-000026), pulled from EDGAR XBRL. Derived measures are computed only from lines shown on this page and the arithmetic is displayed so it can be checked. PFE is not in the tracked book. Market posture attaches only when the dashboard feed carries the name; this page computes none of it.